Format

Send to

Choose Destination
J AAPOS. 2014 Jun;18(3):266-70. doi: 10.1016/j.jaapos.2014.01.016.

Risk and clinical course of retinopathy of prematurity in 78 infants of gestational age 22-25 weeks.

Author information

1
Department of Ophthalmology, Children's National Medical Center and The George Washington University, Washington, DC; Department of Pediatrics, Children's National Medical Center and The George Washington University, Washington, DC. Electronic address: mmiller@childrensnational.org.
2
Department of Pediatrics, Children's National Medical Center and The George Washington University, Washington, DC.
3
The Retina Group of Washington, Washington, DC; Department of Ophthalmology, Georgetown University, Washington, DC.
4
Department of Ophthalmology, Children's National Medical Center and The George Washington University, Washington, DC.
5
Division of Biostatistics and Study Methodology, Children's National Medical Center, Washington, DC.
6
Division of Biostatistics and Study Methodology, Children's National Medical Center, Washington, DC; Biostatistics and Epidemiology, The George Washington University, Washington, DC.

Abstract

PURPOSE:

To characterize the retinopathy of prematurity (ROP) and survival of infants born at gestational age (GA) of 22-25 weeks.

METHODS:

This study was a comparative case series for the total set of 78 infants ≤25 GA screened for ROP at a level IV NICU during a 21-month period. Data are presented on infants screened for ROP from 6 weeks after birth for 22 and 23 weeks' GA infants and from 5 weeks after birth for 24 and 25 weeks' GA. Accounting for the competing risk of mortality, we implemented Cox CR regression models to assess birth weight, GA, and admission diagnosis as potential risk factors for the following time to event outcomes: type 1 disease, aggressive posterior ROP (AP-ROP), plus disease, first presentation of ROP, and worst ROP observed.

RESULTS:

Risk of laser treatment (subhazard ratio [SHR] = 0.56, P = 0.007) and of plus disease (SHR = 0.49, P = 0.001) was increased among those born at lower GA. Twenty infants required laser for type 1 disease at median postmenstrual age (PMA) of 35.8 weeks (range, 33.0-42.7); infants with AP-ROP had laser at PMA of 34.5 weeks (range, 33.0-36.9), 2 weeks earlier than infants without AP-ROP at PMA 36.5 weeks (range, 33.9-42.7). The cumulative probability of receiving laser therapy approached 46% (22 or 23 weeks' GA), 30% (24 weeks' GA), and 18% (25 weeks' GA).

CONCLUSIONS:

The 2013 screening guidelines appear to be appropriate for infants of 22 and 23 weeks' GA when ROP screening begins at PMA 31 weeks.

PMID:
24924282
PMCID:
PMC4137242
DOI:
10.1016/j.jaapos.2014.01.016
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center